What is Trisalus Life Sciences?
Trisalus Life Sciences is an emerging immuno-oncology enterprise dedicated to transforming the treatment landscape for liver and pancreatic tumors. The company distinguishes itself through the development of novel delivery technologies, most notably its proprietary Pressure-Enabled Drug Delivery infusion system. This platform is designed to administer therapeutics directly into visceral organ solid tumors, effectively bypassing traditional systemic limitations.
By pairing its delivery system with investigational agents like SD-101, Trisalus aims to reprogram the immunosuppressive cell populations that typically shield tumors from the body's immune response. This dual-action approach—combining mechanical delivery with biological immunotherapy—positions the company at the intersection of medical device innovation and pharmaceutical development. As the firm scales, its focus remains on improving patient outcomes by enhancing the efficacy of checkpoint inhibitors within the challenging solid tumor microenvironment.
How much funding has Trisalus Life Sciences raised?
Trisalus Life Sciences has raised a total of $122.6M across 8 funding rounds:
Unspecified
$3.7M
Series A
$6.1M
Unspecified
$16.4M
Series B
$18.2M
Series C
$15M
Series D
$12.9M
Debt
$350K
Debt
$50M
Unspecified (2011): $3.7M, investors not publicly disclosed
Series A (2011): $6.1M led by High Country Venture and Partisan Management Group
Unspecified (2013): $16.4M, investors not publicly disclosed
Series B (2013): $18.2M featuring Partisan Management Group, MCG Partners, and High Country Venture
Series C (2015): $15M backed by Tullis Health Investors
Series D (2017): $12.9M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2024): $50M supported by OrbiMed
Key Investors in Trisalus Life Sciences
OrbiMed
OrbiMed is a specialized healthcare investment firm managing capital across biopharmaceuticals, medical devices, and digital health, known for its hands-on approach to strategic initiatives and operational optimization.
High Country Venture
High Country Venture is a Boulder-based venture capital firm that focuses on early-stage investments in scalable, innovative technologies within the life sciences, biotechnology, and medical device sectors.
Tullis Health Investors
Tullis Health Investors is a private equity firm specializing in high-growth, commercial-stage healthcare companies, with a focus on building long-term value in medical devices, specialty pharmaceuticals, and biotechnology.
What's next for Trisalus Life Sciences?
Looking ahead, the strategic deployment of $50M will likely focus on the advancement of clinical trials and the potential acquisition of complementary immuno-oncology assets. The company's roadmap involves refining its Pressure-Enabled Drug Delivery system to ensure broader clinical utility and scalability. By maintaining a focus on the immunosuppressive microenvironment, Trisalus is poised to establish new standards of care for patients with visceral organ malignancies.
The firm's ability to attract high-caliber institutional support suggests a strong market confidence in its long-term vision. Future milestones will likely center on data readouts from ongoing studies and the potential for strategic partnerships that could further validate its unique therapeutic delivery model. As the company transitions into more advanced stages of development, its emphasis on operational excellence and clinical rigor will be critical in navigating the complexities of the global oncology market.
